Premium
Developing and validating SARS‐CoV‐2 assays for nonhuman primate surveillance
Author(s) -
Yee JoAnn,
Carpenter Amanda,
Nham Peter,
Halley Bryson,
Van Rompay Koen K. A.,
Roberts Jeffrey
Publication year - 2022
Publication title -
journal of medical primatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 42
eISSN - 1600-0684
pISSN - 0047-2565
DOI - 10.1111/jmp.12604
Subject(s) - multiplex , nonhuman primate , immunoassay , virology , primate , non human primate , covid-19 , microbead (research) , biology , antibody , medicine , immunology , pathology , bioinformatics , infectious disease (medical specialty) , biochemistry , disease , evolutionary biology , neuroscience
In early 2020, the California National Primate Research Center implemented surveillance to address the threat of SARS‐CoV‐2 infection in its nonhuman primate colony. Materials/Methods To detect antiviral antibodies, multi‐antigen assays were developed and validated on enzyme immunoassay and multiplex microbead immunofluorescent assay (MMIA) platforms. To detect viral RNA, RT‐PCR was also performed. Results/Conclusion Using a 4plex, antibody was identified in 16/16 experimentally infected animals; and specificity for spike, nucleocapsid, receptor binding domain, and whole virus antigens was 95.2%, 93.8%, 94.3%, and 97.1%, respectively on surveillance samples. Six laboratories compared this MMIA favorably with nine additional laboratory‐developed or commercially available assays. Using a screen and confirm algorithm, 141 of the last 2441 surveillance samples were screen‐reactive requiring confirmatory testing. Although 35 samples were reactive to either nucleocapsid or spike; none were reactive to both. Over 20 000 animals have been tested and no spontaneous infections have so far been confirmed across the NIH sponsored National Primate Research Centers.